All In Biotech

Drug Trial Radar · NCT02621892

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Last checked: Nov 19, 2026Latest source record: Apr 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 606 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

606

Actual

Start

Oct 2015

Primary completion

Mar 2017

Study completion Apr 2017

Sponsor

Lead sponsor
ArdelyxIndustry
Sponsor type
Industry
First posted
Dec 4, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 3, 12-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by the ROME III criteria and who have active disease as determined after a two-week screening period. Subjects who qualify and are randomized into the study will either receive 50mg BID of tenapanor or placebo BID for 12 week treatment period and then undergo a 4 week placebo controlled randomized withdrawal.

Conditions

  • Constipation Predominant Irritable Bowel Syndrome

Interventions

  • TenapanorDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 6 of 12 Week Overall Responder RateTime frame: 12 weeks

Locations

111 sites in 1 country. Site status is shown where the registry gives one.

  • Ardelyx Investigative Site 149

    Birmingham, Alabama

  • Ardelyx Investigative Site 114

    Birmingham, Alabama

  • Ardelyx Investigative Site 103

    Huntsville, Alabama

  • Ardelyx Investigative Site 100

    Huntsville, Alabama

  • Ardelyx Investigative Site 145

    Chandler, Arizona

  • Ardelyx Investigative Site 210

    Phoenix, Arizona

  • Ardelyx Investigative Site 296

    Phoenix, Arizona

  • Ardelyx Investigative Site 277

    Tempe, Arizona

  • Ardelyx Investigative Site 269

    Tucson, Arizona

  • Ardelyx Investigative Site 187

    Tucson, Arizona

  • Ardelyx Investigative Site 199

    Tucson, Arizona

  • Ardelyx Investigative Site 140

    Harrisburg, Arkansas

  • Ardelyx Investigative Site 274

    Little Rock, Arkansas

  • Ardelyx Investigative Site 161

    Little Rock, Arkansas

  • Ardelyx Investigative Site 122

    Little Rock, Arkansas

  • Ardelyx Investigative Site 129

    North Little Rock, Arkansas

  • Ardelyx Investigative Site 105

    Canoga Park, California

  • Ardelyx Investigative Site 143

    Chula Vista, California

  • Ardelyx Investigative Site 146

    Encino, California

  • Ardelyx Investigative Site 147

    Encino, California

  • Ardelyx Investigative Site 107

    Lomita, California

  • Ardelyx Investigative Site 112

    North Hollywood, California

  • Ardelyx Investigative Site 110

    Northridge, California

  • Ardelyx Investigative Site 294

    San Diego, California

  • Ardelyx Investigative Site 108

    Thousand Oaks, California

  • Ardelyx Investigative Site 178

    Cutler Bay, Florida

  • Ardelyx Investigative Site 131

    Fort Lauderdale, Florida

  • Ardelyx Investigative Site 136

    Hialeah, Florida

  • Ardelyx Investigative Site 130

    Hialeah, Florida

  • Ardelyx Investigative Site 287

    Homestead, Florida

  • Ardelyx Investigative Site 106

    Miami, Florida

  • Ardelyx Investigative Site 127

    Miami Lakes, Florida

  • Ardelyx Investigative Site 123

    Miami Springs, Florida

  • Ardelyx Investigative Site 126

    Pompano Beach, Florida

  • Ardelyx Investigative Site 132

    Port Orange, Florida

  • Ardelyx Investigative Site 150

    St. Petersburg, Florida

  • Ardelyx Investigative Site 254

    West Palm Beach, Florida

  • Ardelyx Investigative Site 234

    Athens, Georgia

  • Ardelyx Investigative Site 138

    Atlanta, Georgia

  • Ardelyx Investigative Site 148

    Atlanta, Georgia

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.